Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth M Jaffee

Showing results (191-200 of 291) with videos related to

Pageof 30
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 22, 2014
PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumorsKevin C Soares, Agnieszka A Rucki, Annie A Wu, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Tumor- and Nerve-Derived Axon Guidance Molecule Promotes Pancreatic Ductal Adenocarcinoma Progression and Metastasis through Macrophage ReprogrammingNoelle R J Thielman, Vanessa Funes, Sanjana Davuluri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activationLeisha A Emens, Justin M Asquith, James M Leatherman, et al.
Cancer Immunity|December 20, 2007
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelinRaffit Hassan, Wolfgang Ebel, Eric L Routhier, et al.
Nucleic Acids Research|November 20, 2025
Comparative assessment of physiochemical metrics for the clustering of adaptive immune receptor repertoiresAlexander A Girgis, Amanda L Huff, Emily Davis-Marcisak, et al.
Genome Biology|May 14, 2021
Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathwaysWon Jin Ho, Rossin Erbe, Ludmila Danilova, et al.
Annals of Surgery|September 4, 2024
Patient-derived Organoid Pharmacotyping As A Predictive Tool for Therapeutic Selection in Pancreatic Ductal AdenocarcinomaNorman G Nicolson, Joseph A Tandurella, Lawrence W Wu, et al.
Annals of Surgical Oncology|October 25, 2017
Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and EffectiveJohn F Ryan, Vincent P Groot, Lauren M Rosati, et al.
Science Advances|October 16, 2024
Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogrammingNoelle R J Thielman, Vanessa Funes, Sanjana Davuluri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2025
A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic AdenocarcinomaParul Agarwal, Matthew Guo, Kabeer Munjal, et al.
Pageof 30

Showing results (191-200 of 291) with videos related to

Sort By:
Pageof 30
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 22, 2014
PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumorsKevin C Soares, Agnieszka A Rucki, Annie A Wu, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Tumor- and Nerve-Derived Axon Guidance Molecule Promotes Pancreatic Ductal Adenocarcinoma Progression and Metastasis through Macrophage ReprogrammingNoelle R J Thielman, Vanessa Funes, Sanjana Davuluri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activationLeisha A Emens, Justin M Asquith, James M Leatherman, et al.
Cancer Immunity|December 20, 2007
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelinRaffit Hassan, Wolfgang Ebel, Eric L Routhier, et al.
Nucleic Acids Research|November 20, 2025
Comparative assessment of physiochemical metrics for the clustering of adaptive immune receptor repertoiresAlexander A Girgis, Amanda L Huff, Emily Davis-Marcisak, et al.
Genome Biology|May 14, 2021
Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathwaysWon Jin Ho, Rossin Erbe, Ludmila Danilova, et al.
Annals of Surgery|September 4, 2024
Patient-derived Organoid Pharmacotyping As A Predictive Tool for Therapeutic Selection in Pancreatic Ductal AdenocarcinomaNorman G Nicolson, Joseph A Tandurella, Lawrence W Wu, et al.
Annals of Surgical Oncology|October 25, 2017
Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and EffectiveJohn F Ryan, Vincent P Groot, Lauren M Rosati, et al.
Science Advances|October 16, 2024
Semaphorin 3D promotes pancreatic ductal adenocarcinoma progression and metastasis through macrophage reprogrammingNoelle R J Thielman, Vanessa Funes, Sanjana Davuluri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2025
A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic AdenocarcinomaParul Agarwal, Matthew Guo, Kabeer Munjal, et al.
Pageof 30